TIGIT Axis Therapies and The Cancer Clinical Trial Landscape

2022 was a challenging year for TIGIT axis therapies with Roche flunking two late stage lung cancer trials with its anti-TIGIT drug candidate, tiragolumab. Even with the promising Arc-7 readout that partners Arcus and Gilead described as good, and an ASCO Expert describe as a possible “…new ‘gold standard’ for patients with lung cancer”, was not good enough to see an increase in the share prices of both companies.

However, despite the setbacks, what remains clear is that TIGIT therapies, whether solo or in combination, have a promising and viable place in future cancer treatments. Roche’s SKYSCRAPER-01 study is ongoing and there is still opportunity for this study to be a positive trial.

The strongly contested race for clinical success in the field has intensified since 2020, with various targeted approaches continuing through clinical development to bring novel TIGIT axis targeted cancer immunotherapies, with optimized safety and efficacy, to patients in need.